论文部分内容阅读
目的:对比采用化疗、放射治疗、细胞因子诱导的杀伤(CIK)细胞+树突状细胞(DC)过继免疫综合治疗局部晚期非小细胞肺癌与单纯同步放化疗的临床疗效。方法:85例局部晚期非小细胞肺癌患者随机分成研究组45例(化放疗+过继免疫)与对照组40例(化放疗),研究组采用NP方案化疗同步放射治疗并序贯CIK细胞与DC综合治疗,对照组采用NP方案化疗同步放射治疗,观察疗效、毒副反应、患者生活存质量及免疫功能。结果:研究组近期有效率80.0%(36/45)明显高于对照组57.5%(23/40,P<0.05),生存质量及免疫功能明显高于对照组,两组毒副反应差异无统计学意义,P>0.05。研究组2年生存率64.4%(29/45)与1年无进展生存率75.6%(34/56)显著高于对照组32.5%(13/40)与45.0%(18/40)(P<0.05),研究组平均生存期25.5个月显著高于对照组17.2个月(P<0.05),1和3年生存率两组差异无统计学意义,P>0.05。结论:采用同步放化疗并序贯培养的CIK细胞与树突状细胞过继免疫治疗局部晚期非小细胞肺癌,临床疗效较好,可延缓患者生存期并提高生存质量。
Objective: To compare the clinical effects of chemoradiotherapy, radiation therapy, cytokine-induced cytotoxicity (CIK) cells and dendritic cells (DC) adoptive immunotherapy in the treatment of locally advanced non-small cell lung cancer and simple concurrent chemoradiation. Methods: Eighty-five patients with locally advanced non-small cell lung cancer were randomly divided into study group (45 cases) (chemoradiation + adoptive immunity) and control group (chemoradiotherapy). The study group was treated with concurrent NP radiotherapy and sequential CIK cells with DC In the comprehensive treatment, the control group received concurrent chemotherapy with NP regimen, and the curative effect, side effects, quality of life and immune function were observed. Results: The effective rate of 80.0% (36/45) in the study group was significantly higher than that in the control group (57.5%, 23/40, P <0.05), and the quality of life and immune function were significantly higher than those in the control group Significance of learning, P> 0.05. The two-year survival rate was 64.4% (29/45) and one-year progression-free survival rate was 75.6% (34/56) in the study group compared with 32.5% (13/40) and 45.0% (18/40) in the control group (P < 0.05). The mean survival time of the study group was 25.5 months significantly higher than that of the control group 17.2 months (P <0.05). There was no significant difference in the 1-year and 3-year survival rates between the two groups (P> 0.05). CONCLUSION: Adopting synchronous chemoradiotherapy and sequential culture of CIK cells and dendritic cells adoptive immunotherapy for locally advanced non-small cell lung cancer, the clinical effect is better, which can delay the patient’s survival and improve the quality of life.